INmune Bio (INMB) 9 May 242024 Q1 Earnings call transcript

Greetings, and welcome to the INmune Bio First Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is my pleasure to introduce Mr. David Moss, CFO of INmune Bio. David?

good and James, you, afternoon, everybody. Thank you INmune Bio's thank for Results. joining for call the for First us We Quarter Financial XXXX With is call me on Dr. the Bio; RJ Dr. of and Tesi, INmune CEO Co-Founder and Officer and INKmune, on natural Mark Lowdell, memory-like Chief Co-Founder INmune an our platform. who'll oncology cell of killer update provide Scientific

the INmune reliance facts of change. any they to with by underlying only of as RJ? us, to future Bio made INmune SEC. There's required cause under made provisions any everyone these conference responses statements and Bio. such the assurance involve to the on this filings, call over that including disclaims be Before the filings risks remind for in Reform XXXX. reflect actual Tesi, turn as see statements forward-looking these of statements, circumstances on statements management and results that statements. as most speak Except we forward-looking our earnings forward-looking differ the of forward-looking as not quarterly on Act begin, harbor uncertainties the those historical factors These are should by statements that recent are now which no RJ the forward-looking Securities to well Undue from information, company's Litigation statements company's call and statements risk obligations CEO circumstances. With law, except disclaimer can date of outcome. the I the or materially facts, may safe the SEC Please forward-looking like statements events to update as behind I'd Dr. release specific to of placed questions as

the I everyone for call. Thank you, thank you David, and joining

reviewing the with will who on Mark capital milestones. At pass period platform provide by financial and incoming the discussion will last fourth arrange remarks I an As conclude in subsequent over program. on first held around the takeaways key continued provide all to the Lowdell, quarter recent it equity usual, the will and of updates we our start and conference then progress and developments some in programs. commentary level, since quarter XPro March. upcoming the highlight platform from call has to update weeks I fronts will our the infusions over steady on David X a our a high results, including my update

to a enroll physicians will XPro as from date and of and cognitive enrollment years. Due trial, will And we our in soon X about impact readout described with patients communicate let promise and disease. will the we I our Phase Alzheimer's everyone enrollment ADXX, XPro two meet in Recently, we of our quality corresponding last the know. Like of health to continue good Phase II I predict in you, the I patient's this predicting that to clinical we want moderate their and because ago, life. highlighted but to that on not patient, pace. a directly use clinical patient our on that of Australian the of the long-term anecdotes rates positive vagaries the that update roughly eagerly week enroll cannot conclusion the last Australia, patients we months who complete the actually development data occur exact for rules We trial or taking by and with and other of II globally enrollment, Phase Alzheimer's one await provided XPro we target is patient exact an in Alzheimer's we after the the know to as you of MCI with to that clip, with you at last enrolled. been of the we we know disease enroll we mild, expect overall patients. patients enrollment sites continue have receive reiterate disease. mid-XXXX. The the Both early trial midyear. treating three called the the But patients release that participated so in press in commitment

had what other We is of has help from sample, results be the and Phase discussion Phase endpoints. clinical press those in the III elements the work to the CDR as may those agreement Phase associated used haven't were with with Phase II that with, trial. To achieve those regulatory Phase driven a drugs. after we trials our this ongoing three companies of all we X trial. And I XPro come validated press tolerated, be ADXX the for a of endpoint the you FDA, trying in other is in believe Phase in be placebo-controlled do. including in with and is in the do in and on better may believe the the respond EMACC. INmune X the to than some function, patients of of We endpoint That finding Alzheimer's our It preclinical X primary with we trial, X CDR. that themselves. I'll with certainly speak disease size data, suffering us decision endpoint available at size important highlighted who evaluable XPro will trial. what The a Long-term been and why better able their you necessary need duration, and dreadful or Alzheimer's do CDR agencies sensitive and be cognition will had if and are months. differ clinical caregivers. both I that recent regular will suspect publicly databases. by cognition patients determine primary as this well to these using The smaller little be allow II is measure like are This If used of with lives clear, patients important that we development be and EMA, is U.S., not patients X viewed clinical trial release, need globally. In the result respectively, authorities, improvement. based on release. powered will to and their the more with we believe and trial those disease in strongly have trials the stable on trials called ongoing will are and recent they understand to cognitive Alzheimer's the early or of data , to cognitive where was scale we be this by video day. We endpoint, primary the The III approval so want be trial, regulatory that MHRA. authorities, elements pivotal is safe, encourage after with patients compared an to but shorter, link of trial a these will I duration that endpoint. the patients the anti-amyloid and in every you the that in will improved in start cognitive Bio. The EMACC. improved we CDR, ADXX, bit small we're the design The are better, treatment disease. patients a the a it that, data, exemplify acceptable AD. Obviously, helping XPro to randomized the and To to are careful a families caregivers step made their our accurately patients has difference process, scale EMACC live and of in shown been we blinded analysis of

statistical to the with that's treated that powered standard in today. our X/X overcome and criteria have just is lecanemab to to we is talking, Alzheimer's This is trials is are best action our when uses a They is enrichment not for expensive strategy. patients they're is be trial biological months or into benefits And decline. Trials for placebo biomarkers precision the drug that on a benefiting limit personal is is you development, This Alzheimer's answer the too. results the That's clinical of to trial. medicine. use XX the in and good advantage stopped allow with their clinical trial is really both ADXX this donanemab and Oncology patients. Disease. patients oncology same company. and a statement and that a asking in it fully an long you clear, trials. long. Shorter issue for Alzheimer's months. exposed we The matched is not are But need XX-month risky that patients at magical patient and X than disease they noise. care. In To enrollment X it mechanism we months the cognitive statistically opinion, trials ADXX the number that of statistical And enrolled could in strategy. derisk drug trials. their information. that this [indiscernible]. the enrichment is a used Precision a placebo because patients should those I gamble knowledge, who a get me XPro That And is that are clinical First, anti-amyloid the standard months is of time X make patient. bad XPro. fact, to long this trials is disease positive clinical patient the is possible to medicine months is where simple demonstrate our how driving the routinely were were in want the about only progress XX-month it of early development. put number of was not neuroinflammation drug X time do that the therapy targeting enrichment advantage to on is at power. This have enrichment called ADXX received placebo. oncology a randomized have to The trial pathology to realize ADXX Alzheimer's trial patient to to biologic that will large under placebo. There's in of as they clinician. everything But a disease? patients, is development nothing my of The the placebo, a There of the trials benefit with statistical unique development, drug drug for The of development in better enrolled drug is trial CNS the that seen we're don't

a using management are We approach. precision

say, population supply the XX the strategy. being and who more open-label extension us quickly than consideration patients more Phase Overall, and and patients variance enrollment and patient but disease is with with as This trial, advantage to difference in the important critical derisked also smart it's of give by data. statistical, Patients in in trial be randomized a trial active are statistician language months the second of the neuroinflammation. of progress be with to have for practical to a label of the the neuroinflammation for a open-label in both and efficacy reality. more capital sort between and to drug II was kind biologic on drug blinded an reliably provide treasure. we is terrible The the patients This subtle in company. relevant Put closed going consumes statistical placebo lower of a Remember, advantages. this design it's delta of and with a open a safety than were large offered months who Alzheimer. To XX increase Having was arm, the thing therapy drug is additional and Alzheimer's enrichment without resources, today's trial well extension. designed, the and reward

end meetings an mechanisms to already FDA efficacy when predict, want not longer of worries trial. with does disease asked no you bio, harm. with many speed development question the RJ will the XX accelerated or question I on II the are We will Phase the ask a months, accelerated of of The for but remind to a that longer the after population, ethical II of and first to safety dilemma. you have approval in neuroinflammation. will Phase the an will of negotiate we want pathways is is show will what AD Alzheimer's we cannot time? I and of II patients efficacy. There's talking Phase will regulatory both not provide no is the early biomarkers through for and the At Phase XPro placebo charter. their more patients this doing believe a once a end we FDA III time, and one to for is, the INmune for will FDA And Phase treated necessarily FDA design Phase target focused and part to in of not this will want day get the The process. authorities trial are trial. with disease. months say? that that The trial. The trial the the qualify XX The trial Tesi III who approval about drugs where place pathway. patients the In in Alzheimer's XPro mind, The effective treated II on safety period my FDA XPro is, with FDA purpose. is purpose have larger again, FDA patient readout of for clinical prove registration data X this file. That the be may predict is demonstrate an what they very question a clinical be we At have to want

our FDA a respond track how action, combined data apply the to we the applications believe Phase and the compelling on activation for of the II cannot and preclinical approval pathophysiology will our of be breakthrough trial. story. a importance data. neuroinflammation will may but clinical be I complete real for unique We predict mechanism We a will we of Alzheimer's with and disease We Phase our status XPro's fast clinical after based eligible

their Finally, you've have about diseases pathophysiology. that CNS XPro heard underlying that many us talk to of be as applied the all can part neuroinflammation

our publications on is drug. a franchise XPro. We with a This CNS XX It have of different the XX is website disease. in future

will depression beyond first disease treatment-resistant that now Alzheimer's develop. For the disease be we

using the on depression Phase announcements further treatment-resistant II have in will near We the program XPro future.

] this to Phase half Mark mic [ drive on progress second Our of enroll Co-Founder that in in Mark? INKmune II goal first now will patient Bio update the year. I the this is to trial the NIH Lowdell, INmune supported of program. CFO and to pass

company. going to be in. in appears I'm to CaRePC. RJ, got typical for for and everyone, thanks, trial you dialing prostate our it's Thanks, many unique called And Yes, to tell with where cancer as we've our ways

a dosing, in in over able sitting and far. over been so infusion minutes as XX they're of NK then outpatient of boring NK cytokines, their First, and from about NK patients XX remarkably memory-like leave. We've intravenous administer having the an to that patients doses NK NK infusion chair immunotherapies typical getting cancer to able targeting require probably patient, given of immune what as preconditioning cells. Unlike received from setting The tumor nor actually those patient's has are as NK know NK-resistant converts the therapies. INKmune for therapy donors, INKmune therapies. boring to because concept, NK phenotype they NK is the this an actually killing we tumor outpatient, is their of is the are Each use it's as now doesn't to destroy cells that resting so include well ability cells the type conventional use activating with chemotherapy cell more for targeting state the and NK-resistant and team are their which expect, don't for patient historical NK cells. do would cytokines importantly, cells clinical any adoptive or kill immunological these require stimulating you NK circulation monitored number in other cells common own to endpoints, been tolerated. in non-cancer trial cells, within Each their

castrate-resistant levels, In we following prostate-specific variables. effects metastatic antitumor DNA. by this trial, (sic) We volume also circulating measure antigen we with prostate PMSA and measure measure tumor scans cancer [ blood ] tumor tumor-related PSMA

all said, rich trial this now outpatient I, I II. The us received as have In to in Phase the infusions they for is X-month therapy, enrolled determine whether a high-dose an trial three have INKmune, drug on II to Phase So XX And previous set pivotal castrate-resistant CaRePC trial, with will men a Phase received data enroll basis disease. at but follow-up. of the expected the metastatic the patients. ready of end is allow

trial, looking latest. be We important clinical four portion been the are at patients logistics data have hard is by fourth future few moment, the patient second or enrolling the months. The Phase the XXXX INKmune year, of opening month, by of open is planned open-label early which three some centers available data enrollment of on patients of the and completed quarter next all development. the in It completed end very trial, we're snapshots II to to the this a XXXX and and team with manufacturing working the this to portion the means the of be over INKmune the of more the will an at and I expect by next September perfecting trial we has Phase that in forward commercial for XXXX. Equally elements for year,

So with part-time aware other the cell the for the authorities be you'll due T in which strategies move regulatory commercial all academic are process scaling I'm ice, to in they by centers my easy, storage gene awful and drugs. wearing I dry adoptive treatment perfected pivotal preparation and hat and cells. We're logistics therapeutic many trial, a the at assays, of quality CAR therapy release on manufacturing the have Because last over will And sure university of for fit we product of immunotherapies ships we as INKmune up the and and problems. years, with required be forward. space logistical I've lot some manufacturing XX fail seen like the promising and post still associated those an and

quality we drug, can therapeutic can the forward. clinical the can make The release drug's we control, summary, trials ship we hospitals the move in can store determine it value as and will drug. the We drug. So

wide hematological of ovarian project, from INKmune Prostate same to [indiscernible] planned the of an malignancies and but papers solid carcinoma solid initial attributes as a moment. we've treat case, cancer NK pivot the Our unique cell developing tumor work into a solid the some is renal them published one preclinical and we're those. transition in in variety tumors, we've not tumor tumors it's cells on to been a cancer, data was and sound well test at of make ideal space. The

obtain will targets INKmune platform, and update the David. these my over the resources, I'd therapy. That now, we Moss next As to the INKmune on financials. Thank you, be discuss co-founder other to the turn for like is call and to David CFO;

Mark. you, Thank

As usual, and of I'll head our overview upcoming we provide before a Q&A results brief our milestones session. financial to

data. like I'd our II closer readout and begin with comments our capital However, equity to on we raises recent INKmune as some Phase get to Alzheimer's

to existing million the I top entire committed and over support of we in $X.X II In how offerings INmune, the million INmune pleased the stock. anniversary first the past we and holders common management, and stock. warrants in worth also to raised the an is purchase million transactions, the team on purchased shares members $XX.X our the respectively. date Alzheimer's warrants $X.XX, align existing company. the separate exercise new the mostly a million and warrants of an of X.X shares for of common stock raise, over is are from average Directors employees in at X.X but proceeds our underscore of initial exercisable price the support accurate weeks following are of earlier and or the of of of greatly investors, Board appreciate of the The few for of $X welcome here XPro. In from shareholders financially success offerings days the line XX X-year approximately cannot of an saw exercise both The $X.XX the have company to the two reporting $X.XX We We program gross and aggregate team per of approximately share. at issued equity two the price registry. data Phase $X.XX million

as the Net loss 'XX for and financials. $X.X was administrative 'XX. $X.X was clinical the for approximately expenses approximately had scale comparable compared million our totaled with reached to the the of the approximately period. At for for with stockholders comparable XX, both sufficient the approximately $XX March cash the common the compared ended March compared company million for our programs. XXXX. quarter million and figure XXXX, at This with operating XXXX, XX, of approximately expenses with quarter XX, quarter period to for does on ended approximately $X.X XXXX, and period million $XX attributable moving development comparable General of million. our raises. into XX, approximately cash plan, we've Now fund recent not March believe equivalents $X.X March on operations million million Research include cash to Based our is we the current ended $X.X

As of outstanding. XX.X approximately May X, XXXX, million the company stock common of shares had

Now treatment key approximately XPro on to top the disease followed focus mid-XXXX, for by the are expected of enrollment enrolled. patient trial some like line last upcoming as Alzheimer's a cause from data I'd Phase in neuroinflammation X the Full of months milestones. II

a for completion second the taking of first this program. in castration-resistant Phase patients week, announced II metastatic part we depression X cohort prostate We the treatment-resistant in patients initiate the year. Last X of half of XPro with of trial in our will

expect X We to cohort shortly. start

the expect enrollment 'XX. portion Phase castration-resistant of We portion complete metastatic the I end in enrollment by II QX the and QX complete Phase of to is of prostate 'XX, the expected trial

the we remaining secured U.K. always, primary on continue of prudent cost Australia recover Although R&D the expenses potential to while with in we've additional focus to objectives funding, a clinical achieving and portion our as

mentioned extension save RJ the open-label in million of couple changes to company trial-related expenses. with dollars regards will recent and a the the Further, drug

I'd questions. puts poll and turn like like equity focus James? a secured your to to thank data, our good to and for In this summary, point, heading in position into you refusion it for meaningful attention. to us time James that recently back remains solely I'd we execution. At on

with [Operator question we'll Shrader from today our take Instructions] And Tom first BTIG.

sort must you to thinking any curious Is RJ, So there in are still monotherapy going guidance able trial? could or III. the thoughts just to Phase your you A-beta about do you role be fever a quick good. But one you're be is you any of some on there's would I'm antibodies stratify or why understand, cells? on thought yet. And expect Just of for things your if thoughts if Mark. boring a turning so then I NK are safe? Mark, historical

Yes.

-- those. So you, A interesting very question let me Tom the about for thank anti-amyloid.

We have signaled very strongly.

We are aware least midyear. some has approved, be to we've that the the What's data therapy. III regard adoption the is slow. think though, the I that will we're these should us to only it to going to are answer important, been And said trial. have at affect you currently combination preclinical about able question expect from Phase place States, more And clinical drugs United how in that

and those when jurisdictions going we be had that trial the So our who But will no by beyond. will the don't potential in anti-amyloid They drugs those approved. approved not the other participants have clinical like drugs the time slow of on Europe, start be once drugs will United doubt. are U.K., who to I Phase believe again, We III, States be are regulatory adoption. there patients be know plenty and Canada,

than on XPro whether point. this different development alone not that for is works actually different are we question Mark, made on We here. I with there? comment may is Alzheimer's a his trial want you may you combination pathway the phone? a not think at Mark -- be answering believe concerned is have a I'm neuroinflammation. David, Mark a So in patients -- do dropped. call to

Europe a what, sort back He's to add they'll and got problems. drug Mark why He's or don't response, him question, in the I'll relation But so see you over inflammatory fever in. your Tom, in dropped. got of safe. is why tell try you -- having a some

here. is Mark

of So a why looking doesn't inflammatory spent at the with question -- no cells we that. and And cells. NK no activated reactions was time activate answer about INKmune. INKmune Well, lot the T fever, it

inflammatory So entirely cytokine in release cell T the syndrome, response see you mediated. is

from released or NK are And that's don't INKmune cytokines activated which inflammatory secrete inflammatory cytokines cells. So an T by CDX even by cytokine. cells,

no associated has inflammatory been type with itself, therapy it So NK reactions.

it. Got

Okay. Thanks on for both. the thoughts

the No, actually a administration INKmune doesn't at side It's question are effects. it's cause cytokines. no, administered because not cytokines sustain of to normally require And the cells that very smart that of all. NK course,

cell targeting. NK specifically it's So

next Joel will with Baird. question come Beatty Our from

for you is the remind one enrollment of trial that between that? Can and the how II cognitive in versus AD, ongoing mix targeting you're is AD. the enrollment Phase mild first The impairment ones early with tracking us mild patients and of have

question. Yes, good

there, So considering on two things, in relevant proof points it's promise my placebo.

We X average have so placebo. a group of gets words, In and placebo. patient to other X to active [indiscernible] enrollment of one

specify mild whether other patients. we really mild twice the way is -- started you expect patients. So words, as enrolling many a although recall, the only it there's -- MCI other with that's like you the two, all In balance. not expect one. Number ones MCI twice as MCI the many as there don't number AD AD, will you written, protocol would mild will or be AD AD than as more X as there's would X will more trial a trial, But be it be an not I early do. Statistically, -- to

I So is But way the to mix. prediction. be it it's right suspect looking it's next. a very that's me -- to will that, hold a to close Don't going about XX-XX XX-XX a be now

open-label patients? that's been some in you case, but clarification. the guess have the extension open-label be it question any the in are dosing continuing just then all And in study share a And there patients a are enrollments study I complete to that -- extension dosed Has closed, to plans data on collected? that or is

Yes.

good come into at by we on randomized the extension were know open-label a a The been trial has complicated entry. always we patients so the they that that's question. blinded that fact have Remember, data know. after the what don't So don't trial we

the figured way we both I as not a of making supply now, Right the really, and small those. because financial task. drug way best drug -- financial haven't So to the by a said, considerations analyze stuff is out because is consideration supply to

best basically to working the with We are the decide sites path.

Some use not them, some if where practical turn kind -- theme company patients not events, discontinued. available of will and it is but of go consideration. on the that's to will happy they this to It's get be a a -- compassionate will is with be not

to goal the for, make results and our ]. is get that's II where Phase focusing on trial, the we're finish commitment [ and we Our we're to resources investors looking sure

come will from question next Our McCarthy Jason Group. with Maxim

can type kind on RJ, of of is little in bit you might I opine question. for thought think what guess of this trial. a you terms want this RJ's timing regulators do

really or biomarkers that in of You drugs, what effective. away you is what the the of that FDA to FDA Alzheimer's that rate that's Like And to of? get approved available Alzheimer's, accepts they're all mild inflammation, between in seemingly already said saw current X because more about care the correlation of with seems and months are inflammatory months of accepting know biomarkers that willingness given expected markers X you X outcomes now early with they amyloid standard disease. can X decline? the to trial be the But just any

a and question, series in good it I'm statements. answer So going of to

months. of months. robust months, expect not is is pretty we after predicting X X all, our X trial First I'm months X quick, results

talk let's about bit little Now the a biomarkers.

you protein, are biomarker amyloid, biomarkers what words, II not glial of but Alzheimer will acidic tau, In FDA maybe of are of The a biomarker need criteria. [ they the is neuroinflammation will neuroinflammation of which ]. of there as consider Alzheimer's, Phase accept enrichment are GFAP, trial convinced for the enrollment. I'm a accept are which biomarkers that FDA, in things Our they biomarkers other acetylcholine fibrillary

of very predict Now we in the show who all for the will blood actually those, get in trial decrease good there's XPro. is news good patients test a II those I and that biomarkers Phase in

in to don't they think because works. in what going neurofilament neuroinflammation my they're tau we surprise neuroinflammation that as to how the make patients on So focus chain have bet might -- know drug stick we're there'll GFAP. response, we a think in and know and biomarkers don't amyloid And to light is no who actually the interest Alzheimer's. interested on be going will be that's they focused and the be think FDA FDA NfL, we But got a that I they is you, mind we've but the don't

in we So group, really I are, significant to think we going predictions. But the very will us on patients. trial. see I patients don't those quite relatively patients be not to as probably predictions. want the racing size for you've XPro think well are that's they're But really going stable. treat time. as impairment. which of And to is force they're that where do be to double the if XXX to that, my placebo my got will Xx next least more a a group think placebo long at cognitive It we

of to kind So to they but start with in you it, it how group, that, the out true decline like I what like and fake go effect with eventually... you then will even far acetylcholinesterase they can something placebo know placebo mean, the where not even a make or inhibitors

In they general, X months, those a before X to on therapy X and certainly that's enrolled, after stable for any Acetylcholinesterase after drugs. for points. inhibitors. two benefit months, you be can don't months. have be Patients so Yes, see

any on many patients my they an who are But the that longer So have enough the enrolled treating in for are be at as patients would drug. doctors that on really long treating drug view. as clinical patient least the been as much are from the [indiscernible], drug it's with the acetylcholinesterase, benefiting no you would know, and themselves they're instance,

profile as interesting. will drugs -- will thing think underway. the that of of efficacy trial think is do to are maintenance on a in profile. those is models. separate animal was will and the Shrader's ones not the anti-amyloid. think we has monotherapy improve patients ask anti-amyloid partner safety question studies they're combination won't the most don't question the anti-amyloid drug the And future. that I therapy be I the those And curious the safe mentioned, first need the if of But prove that's addition both with combination may the question That hopefully that trial be group an I be by a we'll is separate earlier because who I asked regarding the that and a

cancer Just to one types. move I tumor of on similarities renal depending renal next, cells quick proportion cancer resources, seems question I cells But cancer of choice potential on of selection prostate to that think T those versus there higher in the INKmune, towards heard have is course. NK earlier the of terms in be to a

Absolutely.

a was are prognostic at those cell with PhD IL-X. heavily infiltrate. years I [indiscernible] a issue. CDX at cell course, have long of last NK cells, there's yes, a cancers patients intact NK for having looking effect cell of NK So spent and And the to the [indiscernible] X the been typically targeting approved examining have a same and cancer there's high high as infiltrated I T who's renal mean, student week, cell renal that negative drugs a benefit And history. infiltrate prognostic a for have who

So to very data cells yes, better NK got lines demonstrate cell and do primed cell that's target after really the been [indiscernible] rationale that carcinoma some we've to they've that, behind renal nice

Our Daniel with will Research. question last Carlson from come Tailwinds

you there II? RJ, just approval opposed as the showing I'm Phase hopefully do about numbers, chance group. placebo to of on those cognition conditional wondering in deep you type post put decline any flat that is talk if the up a

heart that Dan, I extraordinary, general, consider the has gets what are [indiscernible] not about to will their FDA knows but excited, all not just along. only like us I they I do groundbreaking an excited. the will the But will -- do. the know excited FDA I like do result, And results push as place. looks extraordinary stops what that has will don't much happen, in in I excited. be the pull be data they and get if tortured as company help investors who the and out us. And the FDA right would believe, only you

Would man, have point, But this on I no. So dinner it? than At more think We'll park, see what just is off. the out are bets say. all a they of to there chance? state bet I a Yes. if we it knock

FDA. such patient vocal the there The the or lot patients a make are adversary of are Dan. Alzheimer's know, a ALS a as great the you DMD. my to of Alzheimer's about I to other field know. indications, with smaller, and groups like it, big compared It's don't difference although not As question. dream groups, some which but I'd breath, particularly advocacy to are I'm not going hold

behind Or about a in FDA? approved it that. on What all sort follow-up might just the elsewhere? going to get they And jurisdictions? of Are results fall line other on those

as get both we a lot we'll of purposes, now of then have disease that the And innovation -- every all I much be I seen The a let's can. are number and through move attempt need all And Alzheimer's we the but because just bit see hesitate to each anti-amyloids the see. haven't thinking. swings need making independent MHRA that line We'll believe that data, little to tends FDA. the this insight they analyzed it innovation and I get ask be II to can to question same. I that to of different. the we'll haven't very little many the they And come Phase think had think And is For quickly. certainly the because that pretty I move is drugs EMA say of is when we me, some that have then a -- one, enrolled, know. tends right? one at we more kind that's regulatory resources only don't think them have in I to to the right top ball, to we we like practical a much as think of quickly look and

Yes.

I there. that's bell So the ring happens seeing you forward when what to look great.

TRD. just one question So about

got Now it? the you and us line you've of refresh tell that more just this trial put something more maybe when out expect about research in, get time of can can to we and capital some and sort there

Well, something blinded, it's a out of again, randomized it. placebo-controlled Once trials.

is thing will and The data, the open. trial getting to actually that the that will way FDA going hear the is go. IND, So has this you're it is the FDA the first accepted announce

we'll of of the First be patient forward. the we then it. trial about enrolled put NIH it behind to grant X/X amount will The related much now, funds resources trial. only Right and -- how the moving the be can speed directly of

put thing this INKmune that a as ahead. the as to So resources able then able has you FDA move we is that primary pedal think But from, we our year, to Alzheimer's, our said, CaRePC. That's the open our first be the resistant have milestones we'll allowed it the mission, And trial. And second should to on is one, because treatment we'll the be goals. we've U.S. hear said, depression. But IND is metal us careful the the expand, and two, the David number because number to to be two patient be will as enrolled.

that I over closing additional session. any for conclude RJ question-and-answer now And the turn today's remarks. will will conference to

Yes. you. thank So

of Alzheimer's prostate support some the early data CaRePC open-label in the complete the capital metastatic success trial, cancer. the of With comfortably we and fundraising, now have castration-resistant into ADXX, the to

provide these to problems in is goal positive readouts. Our readout with positive

the -- able be we to we'll allow have pursuing primary who resources, get, more to tend to uses given capitalize [ capital their products teams and these its aggressive we partners THE in meet alone on company way access a indications. other expect Both markets to we with beyond the that goals. the activities with expertise of those believe We either resources in with And to or hope become have ]. the we

you For your very Thank we support. appreciate much. now,

conference your today's conclude does call. Thank you This for participation.

disconnect. now may You